MassDevice

Johnson & Johnson MedTech has encouraging Omnypulse results, more data backs Varipulse

Johnson & Johnson MedTech (NYSE:JNJ) today announced 12-month pilot data from a study of its investigational Omnypulse ...

Johnson & Johnson Highlights Pipeline Breadth Across Cardiology, Oncology And Vision Care

Johnson & Johnson (NYSE:JNJ) reports strong 12 month pilot-phase data for its OMNYPULSE platform in atrial fibrillation treatment. The company shares expanded safety data for its VARIPULSE platform, ...
MedTech Dive

4 takeaways from the 2026 AF Symposium

Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...
MassDevice

Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter

Johnson & Johnson MedTech (NYSE: JNJ) today announced the full commercial release of its NuVision Nav ultrasound catheter.
Standard-Journal

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

The VARIPULSE Platform is Johnson & Johnson MedTech’s Pulsed Field ablation system. The fully integrated platform includes ...

Johnson & Johnson reports 90% AFib freedom in early heart device study

Johnson & Johnson JNJ on Friday after hours released data from the OMNY-AF pilot study, a prospective, single-arm, multi-center trial. The study pairs the OMNYPULSE Catheter, a 12 mm large-tip focal ...